$Amphastar Pharmaceuticals (AMPH.US)$🎯 2024.4.9 Current pri...

New data: In 23Q4, revenue increased by 31.9%, operating profit increased by 42.7%, and net profit increased by only 6.7% due to interest expenses and other revenue.

In 2023, revenue increased by 29.1%, operating profit increased by 83.3%, net profit increased by 50.5%, and return on net assets increased to 23.6%.

Affected by the acquisition, the balance ratio increased from 28.8% to 57.7%, and total assets and net assets increased significantly. There has been an increase in asset-side cash and receivables, mainly in intangible assets. Long-term debt-side borrowing increased to $590 million, accounting for 92% of the net assets of 640 million.

The current price-earnings ratio is 15.8, and the discount compared to the recent growth rate is very high. Although the debt ratio is also very high, the acquisition effect seems pretty good, and the acquisition process generates very little goodwill, and the risk of intangible asset impairment is low, so you can still choose carefully (⭐️)